Jessica Perl - 03 Mar 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
SVP, General Counsel, Corp Sec
Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
03 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 21:19:36 UTC
Previous filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Perl Jessica SVP, General Counsel, Corp Sec 300 PROFESSIONAL DRIVE, GAITHERSBURG /s/ Richard S. Lindahl, Attorney-in-fact 05 Mar 2026 0002043716

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Tax liability -6,465 -9.6% $8.44* 61,004 05 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Option (Right to buy) Award +46,702 +49% $0.000000* 142,647 03 Mar 2026 Common Stock 46,702 $8.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.